









Markets
/
Stocks
/
nasdaq-phvs
/

Pharvaris NV

PHVS



View Detailed Chart

23.780USD

-0.220-0.92%

Close 08/27, 16:00（ET）Quotes delayed by 15 min

1.30BMarket Cap

LossP/E TTM



Pharvaris NV

23.780

-0.220-0.92%

Overview Company Financials Analysis

Analysis

Intraday

30m

Today

-0.92%

5 Days

+3.39%

1 Month

+15.32%

6 Months

+52.83%

Year to Date

+24.05%

1 Year

+28.54%

View Detailed Chart

Its valuation is considered fairly valued,and institutional recognition is very high.Over the past 30 days, multiple analysts have rated the company as a Buy.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

226 / 690

Overall Ranking

344 / 4755

Industry

Pharmaceuticals & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analysts' Target

Based on 11 analysts

Buy

Current Rating

33.273

Target Price

+38.64%

Upside Space

Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 136.07.

Undervalued

The company’s latest PE is -9.13, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 52.21M shares, decreasing 2.58% quarter-over-quarter.

Held by Andreas Halvorsen

Star Investor Andreas Halvorsen holds 3.65M shares of this stock.